Drug Development Pharma - January 28, 2015
FDA Approves Generic Nexium
AstraZeneca’s extended protection period for the $3 billion-selling heartburn drug Nexium has come to an end, now that the U.S. Food and Drug Administration (FDA) has approved the first generic version of Nexium. Ivax Pharmaceuticals, Inc., a subsidiary of Teva Pharmaceuticals USA, has won approval to market the medication in 20 and 40 milligram capsules. […]
Pharma Business - January 27, 2015
Group Protests AZ Lab Plans
An online petition opposing AstraZeneca PLC’s plans to build an animal testing lab as part of a proposed research center has collected almost 5,000 signatures in fewer than two weeks. The animal rights activist organization Cambridge against AstraZeneca PLC Planning, or CAP, is opposed to the proposed animal testing facilities at the planned site. The […]
New Market - January 27, 2015
Novo to Market Saxenda in U.S.
Novo Nordisk plans to put 500 U.S. sales reps, or about one-sixth of that country’s sales force, to work marketing its newly-approved weight-loss drug Saxenda, a reformulated version of diabetes drug Victoza (liraglutide). In an interview with the Financial Times, Novo Chief Science Officer Mads Krogsgaard Thomsen said his company is looking to generate at […]
Drug Development Pharma - January 26, 2015
EMA Accepts AZ Gout Drug
AstraZeneca’s application for lesinurad, an unevenly successful gout treatment, has been accepted by the European Medicines Agency (EMA). AstraZeneca acquired lesinurad as part of the $1.3 billion purchase of Ardea Biosciences in 2013. The EMA’s Committee for Medicinal Products for Human Use now will decide whether to grant approval to lesinurad to supplement the usual […]
In a new job - January 26, 2015
Targovax Names 2 Executives
Targovax of Norway appointed two new executives, effective Jan. 5. Anne-Kirsti Aksnes, PhD, the new vice president of clinical development, has 20 years of experience within clinical research and development in pharmaceuticals and biotechnology industries and 10 years of experience in clinical physiology. Previously, she was the vice president for clinical research in Algeta ASA […]
Pharma Business - January 23, 2015
Recipharm Issues Bonds
Sweden’s Recipharm AB issued convertible bonds with a nominal value of EUR 50 million as part of the financing of the acquisition of the Corvette Pharmaceutical Services Group completed Oct. 1, 2014. The bonds can be converted into up to 5,030,549 class B-shares. The holders of the convertible bonds have agreed to a lock-up in […]
